AI and the Pharmaceutical Industry — 2026-11-20 (Fri)
This section covers corporate investment behaviour of pharmaceutical companies, not the efficacy or safety of any medicinal product. Headlines are quoted as published; no claim about product performance is made or implied by this site. Collection and classification are automated and may misclassify or miss items. Disclaimer
| Amount | Deal | Function | Source |
|---|---|---|---|
| $5B | Isomorphic adds Merck to AI drug discovery roster days after $5B raise | 🧬 Drug Discovery | Fierce Biotech |
| $5 billion | Isomorphic Labs raises $5 billion, expanding its clinical development foundation for AI drug discovery | 🧬 Drug Discovery | 財経新聞 |
| $5bn | Greenoaks, Sequoia lead $5bn Series C for AI drug developer Isomorphic Labs | 🏛️ Enterprise AI Platform & Governance | Alternatives Watch |
| $110 million | Boltz raises $110 million to expand AI tools for drug discovery | 🧬 Drug Discovery | The Pharma Letter |
| $12 Million | Geodesic's Gu Quanquan: $12 Million in Compute Burned in Six Months, and AI Drug Discovery's Moat Is GPUs, Not Wet Labs | 🧬 Drug Discovery | BigGo Finance |
| — | Novartis guides to 5% annual sales growth through 2031 and raises peak sales targets for Kesimpta, Scemblix and Leqvio | 🏛️ Enterprise AI Platform & Governance | MLQ.ai |
Overview
The biggest move was Isomorphic Labs raising a $5bn Series C and then adding Merck (MSD) as an AI drug discovery partner shortly afterward. Funding and a tie-up with a major pharmaceutical company followed within a few days, strengthening both its capital base and its customer base at once. Today's coverage was concentrated in drug discovery, with little in other areas.
By Category
Drug Discovery Isomorphic Labs and Merck have partnered on AI-driven drug discovery in oncology. The headlines give neither the value nor the terms of the deal; the only thing confirmed is that Merck has joined as a customer. Boltz raised $110 million, reportedly to expand its AI drug discovery tools. Gu Quanquan of Geodesic said the company used $12 million of compute over six months, and argued that the barrier to entry in AI drug discovery is GPUs, not wet labs. This is the speaker's own view and cannot be called a shared understanding across the industry.
Distribution and Supply Chain The only item here is a STAT News roundup whose headline mentions a Merck AI deal. Topics on China and the pharmaceutical supply chain appear alongside it, but the headlines alone do not show how they relate to AI procurement.
Enterprise AI Infrastructure and Governance Greenoaks and Sequoia led Isomorphic Labs' Series C. This is the same deal seen from the investors' side. The Novartis article covers guidance of 5% annual sales growth through 2031, and its headline has no AI element. Placing it in this category is awkward, and it cannot be read as a signal on AI investment.
Reading the Investment Map
Money is flowing toward concentrated funding of drug discovery AI companies that own foundation models. Isomorphic Labs' $5bn stands out, roughly 45 times Boltz's $110 million. Both are funding reports; the amounts pharmaceutical companies are paying and the sizes of their contracts do not appear in the headlines. The value of the Merck partnership is also undisclosed. Geodesic's $12 million is not an investment amount but the compute spend the company claims. One view put forward is that the center of gravity in the business lies in securing compute rather than laboratory equipment.
What to Watch
- Whether contract terms or amounts are disclosed for the Merck and Isomorphic Labs partnership. - Whether Isomorphic Labs' partners expand beyond Merck. If so, that would support the idea that the capital raised is translating into customer wins.
- S4 Amount disclosedIsomorphic adds Merck to AI drug discovery roster days after $5B raise$5B — Fierce Biotech11/19 22:47 JSTMerckAlso reported by 4: MobiHealthNews · BioXconomy · The Pharma Letter · grafa.com
- S4 Amount disclosedBoltz raises $110 million to expand AI tools for drug discovery$110 million — The Pharma Letter11/19 19:20 JSTAlso reported by 1: MLQ.ai
- S4 Amount disclosedGeodesic's Gu Quanquan: $12 Million in Compute Burned in Six Months, and AI Drug Discovery's Moat Is GPUs, Not Wet Labs$12 Million — BigGo Finance11/19 20:08 JST
- S2 Deal / PartnershipMerck Partners With Isomorphic Labs to Advance AI-Powered Cancer Drug Discovery — Yahoo Finance11/19 22:36 JSTMerckIsomorphic LabsAlso reported by 1: marketscreener.com
- S2 Deal / PartnershipIsomorphic Labs and MSD partner on AI-powered discovery of cancer therapies — Unite.AI11/19 21:01 JSTMSDIsomorphic LabsAlso reported by 1: Securities.io
- S2 Deal / PartnershipSTAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more — STAT News11/19 22:36 JSTMerckIsomorphic Labs
- S3 Capital moveNovartis guides to 5% annual sales growth through 2031 and raises peak sales targets for Kesimpta, Scemblix and Leqvio — MLQ.ai11/19 17:42 JSTNovartis